2002
DOI: 10.1210/endo.143.5.8850
|View full text |Cite
|
Sign up to set email alerts
|

Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity

Abstract: The fibroblast growth factors (FGFs), and the corresponding receptors, are implicated in more than just the regulation of epithelial cell proliferation and differentiation. Specifically, FGF23 is a regulator of serum inorganic phosphate levels, and mice deficient in FGF receptor-4 have altered cholesterol metabolism. The recently described FGF19 is unusual in that it is nonmitogenic and appears to interact only with FGF receptor-4. Here, we report that FGF19 transgenic mice had a significant and specific reduc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

14
290
0

Year Published

2003
2003
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 483 publications
(308 citation statements)
references
References 57 publications
14
290
0
Order By: Relevance
“…These negative findings raise the interesting possibility that FGF21 might induce Pgc1␣ through an indirect mechanism involving the central nervous system. FGF21 functions as a potent insulin sensitizer in various animal models of insulin resistance and diabetes (15,17,36,37). Our data suggest that FGF21 does not improve glycemic control by suppressing hepatic gluconeogenesis per se.…”
Section: Discussionmentioning
confidence: 73%
“…These negative findings raise the interesting possibility that FGF21 might induce Pgc1␣ through an indirect mechanism involving the central nervous system. FGF21 functions as a potent insulin sensitizer in various animal models of insulin resistance and diabetes (15,17,36,37). Our data suggest that FGF21 does not improve glycemic control by suppressing hepatic gluconeogenesis per se.…”
Section: Discussionmentioning
confidence: 73%
“…Recently, FGF19 and FGF21 have emerged as candidate members of the FGF ligand family that have impact on the liver, although it is unclear whether the effect on hepatocytes is direct or indirect. Transgenic animals with FGF19 targeted to muscle exhibit an increased metabolic rate and decreased adiposity accompanied by a reduction in expression of liver acetyl CoA carboxylase 2 and triglyceride levels 36 and liver abnormalities associated with cancer in aging mice. 37 FGF21 appears to be specifically expressed in the liver 38 hepatocyte-specific FGFR4 functions and nonparenchymal cells of liver expressing other FGFR isotypes is under investigation.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, acidic glycosaminoglycans in the form of heparan sulfate proteoglycans function to retain these FGFs in the vicinity of FGF-producing sites, such that they primarily act in a paracrine manner. By contrast, the hFGFs have low-affinity heparin-binding sites and have been found to act in an endocrine manner (Tomlinson et al, 2002;Lundasen et al, 2006;Kharitonenkov et al, 2005Kharitonenkov et al, , 2007Fukumoto and Yamashita, 2007;Liu and Quarles, 2007).…”
Section: Identification Of the Mouse Fgf Gene Familymentioning
confidence: 99%
“…In addition, acidic glycosaminoglycans limit the diffusion of FGFs, localizing their activity to the vicinity of FGF-producing cells (Flaumenhaft et al, 1990). In contrast, hFGFs have poor heparin-binding affinity and act on target cells far from their site of production in an endocrine manner (Tomlinson et al, 2002;Lundasen et al, 2006;Kharitonenkov et al, 2005Kharitonenkov et al, , 2007Fukumoto et al, 2007;Liu et al, 2007). In addition, FGF15, FGF21, and FGF23 require co-receptors, Klotho or ␤Klotho, to activate FGFRs (Ogawa et al, 2007;Urakawa et al, 2006).…”
Section: Perspectivesmentioning
confidence: 99%